OLIPASS Corporation (KOSDAQ:244460)
South Korea · Delayed Price · Currency is KRW 1,651.00
-267.00 (-13.92%)
At close: Apr 7, 2025
OLIPASS Revenue
OLIPASS had revenue of 1.81B KRW in the quarter ending September 30, 2023, with 811.99% growth. This brings the company's revenue in the last twelve months to 5.25B, up 190.70% year-over-year. In the year 2022, OLIPASS had annual revenue of 2.30B with 169.56% growth.
Revenue (ttm)
5.25B
Revenue Growth
+190.70%
P/S Ratio
1.60
Revenue / Employee
67.32M
Employees
78
Market Cap
8.40B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 2.30B | 1.44B | 169.56% |
| Dec 31, 2021 | 851.78M | -2.01B | -70.23% |
| Dec 31, 2020 | 2.86B | 1.16B | 67.75% |
| Dec 31, 2019 | 1.71B | 1.22B | 249.26% |
| Dec 31, 2018 | 488.26M | 376.33M | 336.22% |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ADBiotech | 14.57B |
| Eutilex.Co.,Ltd | 10.54B |
| The Technology | 8.75B |
| Genotech | 7.28B |
| SCM Lifescience | 1.54B |
| Kainos Medicine | 938.87M |
| Angiolab | 702.62M |
| Epibiotech | 449.62M |